Twist Bioscience Intrinsic Value Calculator – Exploring if Twist Bioscience is a Smart Investment or a Value Trap
December 20, 2023
☀️Trending News
Twist Bioscience ($NASDAQ:TWST) is a biotechnology company that specializes in the synthesis of DNA, RNA, and other molecules for research and development. The company has developed a high-throughput, silicon-based platform that is used to make DNA for a variety of applications. With the rise of genomics and gene-editing techniques, Twist Bioscience’s platform has become increasingly popular. It has attracted investment from major investors and companies, making it one of the most talked-about companies in the biotech sector. When considering investing in Twist Bioscience, it is important to analyze both its potential upside and downside. On the one hand, the company has a promising technology and a strong customer base.
It has achieved strong growth in the past few years and has a substantial presence in the biotechnology sector. On the other hand, its technology is yet to be proven, and its stock is highly volatile. As such, it is important to consider all of these factors before investing in Twist Bioscience. In conclusion, whether to invest in Twist Bioscience or not is largely dependent on one’s individual risk appetite and financial objectives. With its potential to deliver strong returns, it could be a smart investment choice, but one should proceed with caution and weigh all the risks before making any decisions.
Share Price
Twist Bioscience is a publicly traded company on the stock market, and on Friday, its stock opened at $35.1 and closed at $34.6, down by 1.5% from its prior closing price of $35.1. As potential investors consider making an investment in Twist Bioscience, they must assess the performance of the company over the last few years to understand whether this decrease in stock value is a trend that is likely to continue, or an isolated incident. They must also evaluate the company’s financial status to determine if it can withstand short-term losses.
Additionally, investors must research the company’s products and services to understand if there is long-term potential in their offerings. By taking all of these factors into consideration, investors can determine if Twist Bioscience is a smart investment or a value trap. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Twist Bioscience. More…
| Total Revenues | Net Income | Net Margin |
| 245.11 | -204.62 | -80.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Twist Bioscience. More…
| Operations | Investing | Financing |
| -123.04 | -232.93 | 270.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Twist Bioscience. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 776.4 | 152.97 | 11.46 |
Key Ratios Snapshot
Some of the financial key ratios for Twist Bioscience are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.6% | – | -83.0% |
| FCF Margin | ROE | ROA |
| -67.3% | -19.3% | -16.4% |
Analysis – Twist Bioscience Intrinsic Value Calculator
GoodWhale recently conducted an analysis of TWIST BIOSCIENCE‘s well-being. After thoroughly evaluating the company’s financials and market trends, we calculated the fair value of TWIST BIOSCIENCE’s share to be around $89.7 using our proprietary Valuation Line. Surprisingly, we have noticed that the stock is currently trading at $34.6, which is a 61.4% undervaluation of the fair value. This presents a great opportunity for investors looking to capitalize on discounted stocks. As such, GoodWhale recommends investors to keep a close eye on TWIST BIOSCIENCE and its stock price movements for potential investment opportunities. More…
Peers
It offers DNA synthesis on a silicon chip, which enables the company to offer its services at a lower cost than its competitors. The company’s competitors include HTG Molecular Diagnostics Inc, Proteome Sciences PLC, and Genedrive PLC.
– HTG Molecular Diagnostics Inc ($NASDAQ:HTGM)
FoundHTG’s cutting-edge molecular diagnostic platform and cancer test portfolio offers clinicians actionable insights to improve patient outcomes. The company’s tests are designed to guide precision cancer treatment decisions by identifying the specific genetic alterations that drive a patient’s tumor.
FoundHTG’s products are available through a global network of distributors and partners. The company’s tests are used in more than 30 countries and have been validated in over 1,000 peer-reviewed publications.
FoundHTG has a market cap of $6.07M and a ROE of -156.17%.
– Proteome Sciences PLC ($LSE:PRM)
Proteome Sciences PLC is a United Kingdom-based company, which is engaged in the business of proteomics. The Company’s primary focus is on the development and application of proteomics technologies for the biomarker discovery, validation and protein profiling across a range of life science research and clinical applications. It operates through two segments: Biomarkers and Protein Analysis. The Biomarkers segment includes the development and commercialization of biomarkers for diagnostics and drug development. The Protein Analysis segment provides contract research services to the pharmaceutical, biotechnology and academic sectors.
– Genedrive PLC ($LSE:GDR)
Genedrive PLC is a molecular diagnostics company. The Company focuses on the development and commercialization of its technology for the diagnosis of infectious diseases and point-of-care testing. It operates through the following segments: Genedrive and Genedrive Asia Pacific. The Genedrive segment comprises the Company’s operations in Europe, the Middle East, Africa and the Americas. The Genedrive Asia Pacific segment comprises the Company’s operations in Asia Pacific.
Summary
Twist Bioscience is a synthetic biology company that provides DNA as a service for businesses and research organizations. The company’s technology has the potential to revolutionize the way DNA is used in many applications, such as medical research and drug development. In terms of investing analysis, the company has seen rapid growth and is currently trading at an all-time high. Analysts are bullish on the stock, with strong expectations for revenue, profits, and cash flow growth in the coming years. Many investors are attracted to the stock due to its cutting-edge technology, potential for disruption, and robust financials.
However, some worry that the company may be overvalued and may not be able to deliver on its lofty promises. Investors should conduct thorough due diligence and carefully consider the potential risks before investing in Twist Bioscience.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
